Last updated: February 23, 2026
What is the drug associated with NDC 00168-0357?
NDC 00168-0357 corresponds to the drug Doxycycline Hyclate, often used as an antibiotic for bacterial infections, including respiratory tract, urinary tract, and Lyme disease. It is marketed under various brand names such as Vibramycin, as well as in generic formulations.
Current Market Landscape
Market Size & Demand
- The global antibiotic market was valued at approximately USD 40 billion in 2021, with doxycycline constituting a significant segment.
- The U.S. antibiotic market reached an estimated USD 20 billion in 2022; doxycycline patents expired in 2011, leading to increased generic competition.
- Doxycycline prescriptions in the U.S. average around 15 million annually (IQVIA, 2022).
Competitive Position
- Market Players: Major generics manufacturers include Teva, Perrigo, Sandoz, Mylan, and Hikma.
- Brand vs. Generic: Doxycycline is primarily available as a generic; brand sales are minimal and limited to specific cases.
- Patent Status: No active patents for doxycycline hyclate; market entry barriers are low.
Distribution Channels
- Generic drugs are primarily sold through pharmacies, hospitals, and mail-order services.
- Increasing utilization in outpatient settings drives steady demand.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Price per 100-count 100 mg Capsules (USD) |
Source |
| 2018 |
$25 |
[1] |
| 2020 |
$22 |
[2] |
| 2022 |
$20 |
[3] |
Prices reflect negotiated wholesale acquisition costs (WAC), not retail prices.
Recent Price Dynamics
- Prices have declined approximately 20-25% over four years, driven by increased generic competition.
- Patent expiration of key formulations in 2011 prompted significant market entry.
Future Price Projections
- Given the saturated generic market, prices are expected to remain stable with slight downward pressure.
- Forecast for 2025: average price around USD 18–20 per 100-count, assuming no major supply chain disruptions or regulatory changes.
Key Factors Affecting Price
- Regulatory Changes: Introduction of antimicrobial stewardship programs may limit unnecessary prescriptions.
- Market Entry Barriers: Low, with most manufacturers capable of producing doxycycline.
- Supply Chain: Raw material availability affects cost structures; recent supply chain issues have caused short-term price fluctuations.
- Emerging Resistance: Growing bacterial resistance could reduce use in some indications, thus impacting demand.
Price Influences and External Factors
Patent Landscape & Regulatory Environment
- No active patents; regulations favor market entry and price competition.
- FDA approval processes are straightforward for generics, with 505(j) abbreviated pathway applied.
Reimbursement & Insurance
- Reimbursement rates align with negotiated prices; insurance coverage largely depends on formulary decisions.
- Out-of-pocket costs for patients are typically in the USD 10–20 range for a standard prescription.
International Markets
- Doxycycline is sold in Europe, Asia, and Latin America, with similar price trends.
- Price differences are driven by local regulatory environment and healthcare policies.
Strategic Insights for Market Participants
- Entry Strategy: Low barriers favor new generic entrants; differentiation is limited.
- Pricing Strategy: Small margins suggest focus on high volume and cost efficiency.
- Distribution Focus: Emphasize outpatient clinics and pharmacy chains where demand remains steady.
- Monitoring Resistance: Watch for resistance patterns that may impact prescribing behavior.
Key Takeaways
- The drug associated with NDC 00168-0357 is doxycycline hyclate, dominated by generics since patent expiry in 2011.
- Market size remains substantial, with annual U.S. prescriptions around 15 million and consistent demand.
- Prices have declined steadily, currently averaging USD 20 per 100-count, with projections indicating stability around USD 18–20 by 2025.
- Barriers to entry are minimal; competition intensity keeps margins thin.
- External factors such as antimicrobial stewardship and resistance impact future demand.
FAQs
1. How does patent expiration influence the price of doxycycline hyclate?
Patent expiration removes exclusivity, allowing multiple manufacturers to produce generics, leading to increased competition and reduced prices.
2. What are the main factors driving doxycycline's demand?
Demand is driven by its broad-spectrum antibiotic activity, safety profile, affordability, and prescribing for conditions like Lyme disease and respiratory infections.
3. Are there upcoming regulatory changes that could impact doxycycline pricing?
Current regulations support generics; no significant upcoming regulatory changes are anticipated; however, antimicrobial stewardship programs may influence prescribing patterns.
4. Which regions have the highest consumption of doxycycline?
The U.S. leads in consumption, followed by Europe and Asia, depending on local prescription practices and disease prevalence.
5. What are the main considerations for companies planning to enter the doxycycline market?
Key considerations include manufacturing costs, supply chain stability, competitive pricing, and adherence to regulatory standards.
References
- IQVIA. (2022). National Prescription Audit.
- Drug Channels Institute. (2020). Drug Price Trends.
- Medicaid Drug Rebate Program. (2022). Average Manufacturer Price Data.
